Moving from Portugal to Dubai, he will be taking over from Sebnem Girgin, General Manager of Turkey
Dubai, United Arab Emirates: Gilead Sciences, a research-based biopharmaceutical company, has appointed Vitor Papao, as the General Manager of its Middle East operations. Moving from Portugal to Dubai, he will be taking over from Sebnem Girgin, General Manager of Turkey, who has been serving as the interim Middle East head over the past few months.
Having joined Gilead in 2007 as Sales Director in Portugal, Vitor went on to take on several senior titles such as Business Unit Director for HIV, in 2008, and Commercial Lead, between 2012 and 2015, for various therapy areas, and manage international remits in the United Kingdom, Europe, Middle East, and Africa. In March 2015, Vitor was selected for the position of General Manager of Gilead Portugal and led the affiliate toward success as it launched a full FTAF portfolio. He also managed the team while it supported the Kite colleagues in establishing a clear leadership in Cell Therapy with Yescarta. His excellent leadership skills allowed him to lead the Russian affiliate as an interim General Manager during a difficult time, starting June 2022, ensuring patients’ access to essential, life-saving medicine.
Vitor Papao, General Manager, Gilead Sciences, Middle East said “I am delighted to take on this challenge and lead a dynamic region such as the Middle East, a leader in adopting innovations to support patients and a rapidly growing market for us with significant growth potential. I am very proud to learn that the team in the region has been delivering innovative treatments that aim to prevent, treat and cure life-threatening diseases such as HIV, cancer, and viral hepatitis, supporting more than 96000 patients between 2014 and 2022.”
As of December 2022, Gilead Sciences has 55 employees supporting 12 markets in the region. In the Middle East, the company has 58 active licenses across its therapeutic areas of HIV, HCV, HBV, Fungal diseases, oncology, and COVID-19.
-Ends-
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For further information, please contact:
Ronak Thakkar, Account Director at FleishmanHillard
E: ronak.thakkar@fleishman.com
© Press Release 2022
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.